A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at ATTD ...

Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be ...